13 Years of Excellence: South Korea’s Biggest Biologics Manufacturing Conference
In the fast-paced and ever-evolving world of biopharma, South Korea continues to assert itself as a global leader, driving innovation through sustained R&D investment and groundbreaking initiatives from both the public and private sectors. South Korea’s exceptional performance in public health during the Covid-19 pandemic has solidified its reputation as a biotech powerhouse on the international stage.
As we look to the future, 14th Biologics Manufacturing Korea 2025 aims to serve as the premier platform for collaboration, knowledge exchange, and strategic partnerships. This year's conference will delve into critical topics, including advanced strategies in upstream processing, the future of biomanufacturing through automation and AI technologies, insights on regulatory pathways for biosimilars and innovative approaches to downstream processing and supply chain optimization.
Biologics Manufacturing Korea 2025 will be co-located with the Cell and Gene Therapy East Asia 2025 and ADC and Bioconjugate East Asia 2025 events, enhancing the opportunity for interdisciplinary discussions and collaboration.
Join us at Biologics Manufacturing Korea 2025 to connect with key players shaping Korea’s biopharma landscape, including leaders from Samsung Biologics, Celltrion, SK bioscience, Hanmi Pharmaceuticals, Lotte Biologics, and more. If Korea is your gateway to growth in the biomanufacturing space, Biologics Manufacturing Korea 2025 is the destination where innovation meets opportunity.
A dialogue among industry leaders examining the current landscape, challenges, and opportunities in South Korea’s biologics manufacturing sector.
Insights into how automation and Industry 4.0 technologies are transforming biomanufacturing processes for enhanced efficiency and quality.
Best practices and innovative strategies for improving cell culture processes to maximize yield and support the development of advanced therapies.
An overview of the regulatory landscape and key considerations for successfully bringing biosimilars to market.
Strategies and technologies to optimize purification processes and improve overall yield in biologics production.
Exploring modern facility design principles and capacity planning strategies to meet the demands of a rapidly evolving biopharma landscape.
Discussing the importance of analytics in maintaining product quality and compliance with regulatory standards throughout the manufacturing process.
Innovative solutions and best practices for optimizing the supply chain, focusing on fill-finish processes and packaging to ensure product integrity.
Coming soon.
Coming soon.
Coming soon.
Coming soon.
Prestige Biologics is established in 2015 and completed its first plant in Chungbuk Osong Life Science Complex in 2018. The four plants have a total manufacturing capacity of 154,000 liters. Plants 1, 2, and 3 are equipped with single-use technology, while Plant 4 has implemented the 'Hybrid ALITA Smart BioFactory™'. 'Hybrid ALITA Smart BioFactory™' combines the advantages of single-use systems and stainless steel, which is achieving outstanding performance.
The facility received GMP certification from the Ministry of Food and Drug Safety (MFDS) in Korea and the European Union (EU) in 2019 and 2021, respectively. US FDA inspections for both campuses are expected in 2025.
Prestige Biologics offers a 'One-Stop Solution' that meets customer needs throughout the entire process of biopharmaceutical production, including manufacturing process development, production of clinical samples, step-by-step regulatory support, and commercial production.
Attending? Contact [email protected] to express your interest.
IMAPAC is the go-to holistic producer of live events, biopharma data and digital marketing solutions for the global biopharmaceutical industry.
© 2024 Imapac. All rights reserved. Trade marks are owned by or licensed to imapac.
IMAPAC requires your contact information to reach out to you about our products and services. You can unsubscribe from these communications at any time. For details on how to unsubscribe and to learn more about our privacy practices and our commitment to protecting your privacy, please review our Privacy Policy.
IMAPAC requires your contact information to reach out to you about our products and services. You can unsubscribe from these communications at any time. For details on how to unsubscribe and to learn more about our privacy practices and our commitment to protecting your privacy, please review our Privacy Policy.